Skip to content
ppharmaranks
Menu
Class IIOngoing

Medroxyprogesterone Acetate Injectable Suspension recall

FDA recall D-0400-2025 · initiated Apr 25, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated May 7, 2025How we research

Mckesson Medical-Surgical Inc. Corporate Office recalled Medroxyprogesterone Acetate Injectable Suspension in Apr 2025 — an FDA Class II recall (D-0400-2025) because Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: 1MP24042, Exp 6/30/26

Quantity recalled: 3

Details

Product
Medroxyprogesterone Acetate Injectable Suspension, USP, 150 mg / mL, 1 mL Single-Dose Vial, Rx only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520, NDC 55150-0330-01
Recalling company
Mckesson Medical-Surgical Inc. Corporate Office
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Distributed to Medical Facilities in MS and FL.
Initiated
Apr 25, 2025
FDA report date
May 7, 2025
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Medroxyprogesterone Acetate Injectable Suspension recalled?
Mckesson Medical-Surgical Inc. Corporate Office recalled Medroxyprogesterone Acetate Injectable Suspension in Apr 2025 — an FDA Class II recall (D-0400-2025) because Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Medroxyprogesterone Acetate Injectable Suspension recalled?
Per the FDA enforcement record, the reason for recall D-0400-2025 was: Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.
Is a recalled Medroxyprogesterone Acetate Injectable Suspension dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Medroxyprogesterone Acetate Injectable Suspension are affected?
Distributed: Distributed to Medical Facilities in MS and FL.. The recall covers these lots — Lot #: 1MP24042, Exp 6/30/26. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0400-2025.

Source: openFDA Drug Enforcement record D-0400-2025

← All drug recalls